AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 18.2261
- Book/Share 14.4548
- PB 6.0643
- Debt/Equity 0.7343
- CurrentRatio 0.8629
- ROIC 0.1094
- MktCap 271233079844.0
- FreeCF/Share 2.8142
- PFCF 31.0904
- PE 32.6929
- Debt/Assets 0.2921
- DivYield 0.0179
- ROE 0.1984
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AZN | Jefferies | -- | Buy | -- | -- | Oct. 27, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Oct. 16, 2025 |
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
Published: November 10, 2025 by: Benzinga
Sentiment: Positive
AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well as safety and tolerability in participants with resistant hypertension.
Read More
AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Negative
The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and EPS growth, but Q4 2025 is expected to show slower or even negative EPS growth. Risks could also stem from U.S. pricing pressures and potentially unresolved tax issues in China. Additionally, stretched valuations and limited near-term upside, prompt a Hold rating.
Read More
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.
Read More
AstraZeneca climbs to net all-time high after US deal reassurance
Published: November 06, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted what analysts called a very solid set of third-quarter results, but the shares barely moved in early morning trading as the City waited for more details on the analyst call. In afternoon trading, shares in the giant drugmaker jumped over 4% to a new all time high above 12,990p.
Read More
Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
AstraZeneca wins shareholder backing for NYSE listing in US pivot
Published: November 03, 2025 by: Reuters
Sentiment: Positive
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
Read More
AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US
Published: November 03, 2025 by: Reuters
Sentiment: Positive
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
Read More
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025
Published: November 03, 2025 by: Accesswire
Sentiment: Neutral
LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will present new data from the safety run-in portion of its ongoing trial evaluating BI-1206 in combination with rituximab and Calquence ® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) in a poster at the upcoming 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Abstract data (as of August 4, 2025) published in the November …
Read More
AstraZeneca to face questions on Trump MFN deal, patent expiries and pipeline
Published: October 31, 2025 by: Proactive Investors
Sentiment: Neutral
When AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reports third-quarter results next Thursday, 6 November, with investors and analysts will be keen to hear about the financial implications of the 'most favoured nation' (MFN) pricing deal recently agreed with Donald Trump, as well as the loss of its Farxiga patent and prospects for new drugs coming out of its pipeline. This will be the first opportunity for discussion of the US MFN deal, making its a key discussion point, according to analysts at UBS.
Read More
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
AstraZeneca unveils expanded manufacturing facility in Texas
Published: October 15, 2025 by: Business Wire
Sentiment: Neutral
COPPELL, Texas--(BUSINESS WIRE)--AstraZeneca today announces the unveiling of its newly-expanded, state-of-the-art manufacturing facility in Coppell, Texas. The expansion project will double the production of Lokelma for the benefit of patients in the United States and around the world. The investment of $445 million to expand the facility follows the groundbreaking last week at AstraZeneca's manufacturing facility in Albemarle County, Virginia. Both are part of AstraZeneca's $50 billion invest.
Read More
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.
Read More
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
Published: October 10, 2025 by: Market Watch
Sentiment: Positive
AstraZeneca PLC looks poised to announce a deal with U.S. President Donald Trump that's focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfizer Inc.
Read More
AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices, according to a person familiar with the matter
Published: October 10, 2025 by: WSJ
Sentiment: Positive
The agreement follows last week's deal with Pfizer.
Read More
Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports
Published: October 10, 2025 by: CNBC
Sentiment: Positive
The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported. President Donald Trump has already agreed to a similar pact with Pfizer, which will sell discounted drugs to Medicaid patients through a website called TrumpRx.gov.
Read More
AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump
Published: October 09, 2025 by: Reuters
Sentiment: Positive
AstraZeneca broke ground on a new plant in Virginia on Thursday and said it would spend $4.5 billion on the facility as drugmakers look to respond to President Donald Trump's call for more medicines to be made in the U.S. and at lower costs.
Read More
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
Published: October 09, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at Rivanna Futures in Albemarle County and is expected to create approximately 3,600 direct and indirect job.
Read More
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
AstraZeneca shares leap with FDA set to review drug to treat breast cancer
Published: October 01, 2025 by: Market Watch
Sentiment: Positive
AstraZeneca shares rallied on Wednesday after the U.K. giant and its Japanese partner said the Food and Drug Administration was reviewing one of its drugs to treat breast cancer.
Read More
AstraZeneca's US listing may pull other firms from London in its wake
Published: September 30, 2025 by: Reuters
Sentiment: Negative
AstraZeneca's move to upgrade its listing in the U.S. risks pulling liquidity away from London's stock market and could pave the way for other large companies to follow suit, analysts, investors and advisers said.
Read More
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products puts over 50% of its free cash flow at risk, despite ongoing U.S. manufacturing expansion. Sanofi's high-margin Dupixent and AZN's broad U.S. portfolio are also vulnerable, though both are investing in U.S. production to seek exemptions.
Read More
AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices
Published: September 26, 2025 by: WSJ
Sentiment: Negative
AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices.
Read More
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
Published: September 26, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery. AstraZeneca Direct will support people living with chronic conditions such as asthma, diabetes, heart failure and chronic kidney disease, and people seeking flu protection. Starting October 1, 2025, eligible patients with prescrip.
Read More
AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.
Read More
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.
Read More
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Astrazeneca (AZN) is a Strong Value Stock
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with nasal polyps.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300